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Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age
and is characterized by chronic anovulation. Insulin resistance may be a key component of the pathogenesis of this
disorder. Pioglitazone is a thiazolidinedione derivative that acts by improving insulin resistance via the peroxisome
proliferator-activated receptor-γ (PPAR-γ) pathway. Reportedly, pioglitazone improves the anovulation status in
patients with PCOS. In the present study, we examined whether pioglitazone directly affects ovarian follicular
development and steroidogenesis using in vitro mouse preantral follicle culture system.
Methods: An isolated individual in vitro mouse preantral follicle culture was used to test the effects of pioglitazone
on the follicle development and steroidogenesis. Tumor necrosis factor-α (TNF-α), which plays a role in insulin
resistance, has been reported to inhibit the follicle stimulating hormone (FSH)-induced follicular development and
steroidogenesis in an in vitro mouse preantral follicle culture system. Therefore, we examined whether pioglitazone
counteracts these effects by TNF-α. We assessed the follicle diameter and follicle survival and antral-like cavity
formation rates, the 17β-estradiol (E2) levels in the culture medium, and the ovulation rate using the in vitro
preantral follicle culture.
Results: Pioglitazone treatment counteracted the inhibition of TNF-α in FSH-induced follicle development in a
dose-dependent manner. Pioglitazone, at a concentration of 5 μM, which was the minimum effective
concentration, significantly counteracted the inhibition of TNF-α in FSH-induced follicle survival (29 versus 56%,
P < 0.05), antral-like cavity formation (29 versus 48%, P < 0.05), E2 concentration in the culture medium (mean ±
SEM = 21 ± 1 versus mean ± SEM = 27 ± 1 pg/mL, P < 0.05), and human chorionic gonadotropin-induced ovulation
rate (9 versus 28%, P < 0.05).
Conclusions: Pioglitazone counteracted the inhibition by TNF-α on FSH-induced follicle development and
steroidogenesis in the in vitro mouse preantral follicle culture. The results suggest that pioglitazone may directly
affect the follicular development and steroidogenesis.
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Polycystic ovary syndrome (PCOS) is a common endo-
crine disorder in women of reproductive age, affecting
5–10% of the population [1], and is characterized by
anovulation and infertility. Although the exact patho-
genesis of PCOS remains unknown, insulin resistance and
compensatory hyperinsulinemia are considered relevant
[2]. Hyperinsulinemia contributes to excessive ovarian
androgen production and the reduction of the hepatic
synthesis of sex hormone-binding globulins, resulting
in an elevated level of free androgen [3,4]. Intraovarian
hyperandrogenism suppresses araomatase activity and
17β-estradiol (E2) production in granulosa cells [5,6] and
proliferation and arresting antral follicle development.
The circulating levels of adipocytokines, such as tumor
necrosis factor-α (TNF-α) and interleukin 6, which raise in-
sulin resistance, are higher in obese and nonobese women
with PCOS than those in weight matched non-PCOS con-
trol women [7,8]. TNF-α is critcically involved in the apop-
tosis of preantral and antral follicles in mouse and human
ovaries [9,10]. Moreover, TNF-α directly affects the ovarian
steroidogenesis in granulosa cells in in vitro culture [11].
Insulin resistance with compensatory hyperinsulinemia
is observed in approximately 70% of patients with PCOS,
irrespective of obesity [12,13]. Several studies have sug-
gested that decreases in insulin secretion improve infertil-
ity and ovulation [14-16]. Therefore, patients with PCOS
are often treated with insulin-sensitizing drugs such as met-
formin and thiazolidinedione derivatives [17]. Pioglitazone
is a thiazolidinedione derivative that has been used for the
treatment of type 2 diabetes mellitus. Pioglitazone de-
creases peripheral insulin resistance via the peroxisome
proliferator-activated receptor-γ (PPAR-γ) pathway [18].
Several studies have demonstrated that pioglitazone im-
proves clinical, hormonal, and metabolic status in patients
with PCOS [15,19-21]. Moreover, pioglitazone directly
inhibits estradiol and testosterone production in human
ovarian cells in vitro [22]. Pioglitazone-stimulated reduc-
tion in peripheral insulin resistance and its direct effect on
the ovaries might be effective for inducing ovulation in
patients with PCOS. However, the direct effects of
pioglitazone on the ovarian follicular development are still
unclear.
We previously established the in vitro mouse pre-
antral follicle culture system to assess the effects of
bezafibrate, a lipid-lowering fibrate, on follicular devel-
opment [23]. As bezafibrate is a nonselective ligand for
PPAR-α, δ, and γ [24,25], we demonstrated that the
bezafibrate may exert direct action on the ovarian fol-
licular development and steroidogenesis through the
PPAR-γ pathway [23]. Because pioglitazone is a specific
PPAR-γ agonist, we hypothesized that pioglitazone may
also directly affect the ovarian follicular development
and steroidogenesis.The aim of this study was to examine whether pio-
glitazone affects the ovarian follicular development and




This study was performed with permission from the Com-
mittee of Animal Experimentation at the Yamagata Univer-
sity Faculty of Medicine. Mature female ICR mice at
6 weeks or older were used in this study. They were
housed in a temperature- and light-controlled room at 23–
25°C, on a 12-h light:dark cycle (lights on, 0700–1900 h)
and fed pellet food and water ad libitum.
Reagents
Human pituitary follicle-stimulating hormone (FSH) (cata-
log no. F4021) and TNF-α (catalog no. T6674), were pur-
chased from Sigma-Aldrich® (St. Louis, MO). Pioglitazone
was kindly donated by Takeda Pharmaceutical Company
Limited, Osaka, Japan.
Collection of preantral follicles
Collection of preantral follicles from the mice was reported
previously [23]. Briefly, female mice were killed by cervical
dislocation, and early preantral follicles were mechanically
isolated from the ovaries using a 30-gauge needle under a
stereomicroscope. The collected preantral follicles were
placed and pooled in N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES)-minimal essential medium
(MEM, catalog no. 12360038; Invitrogen Corp, Carlsbad,
CA) supplemented with 5% fetal bovine serum (FBS; cata-
log no. 12603c; JRH bioscience, Lenexa, KS). After washing
with HEPES-MEM 2 times, follicles with the following
characteristics were selected: (1) diameter, 120–150 μm; (2)
immature oocyte centrally located within the follicle; (3) in-
tact basal membrane; and (4) surrounded by theca cells
[26]. These procedures were performed at 37°C.
In vitro preantral follicle culture
In vitro preantral follicle culture was reported previ-
ously [23]. The follicle culture medium consisted of α-
MEM GlutaMax™ (catalog no. 32561037; Invitrogen
Corp., Carlsbad, CA) supplemented with 5% FBS, 100
units/mL penicillin, 100 μg/mL streptomycin, 5 μg/mL
insulin, 5 μg/mL transferrin, and 5 ng/mL selenium
(ITS; Invitrogen Corp., Carlsbad, CA). The medium was
sterilized with a 20-μm pore filter after the addition of
supplements, which resulted in the basal medium. As
FSH treatment at 100 mIU/mL was the minimum ef-
fective concentration for developing follicles (data not
shown), 100 mIU/mL FSH were added to the basal
medium in the in vitro follicle culture system. Follicles
were individually cultured per well in a 24-well plate
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NJ) containing 1 mL culture medium at 37°C with 5% CO2
in air atmosphere. Follicles were cultured for 13 days. Sub-
sequently, follicular growth was monitored every 2 days
(day 2, 4, 6, 8, 10, and 12 of culture) under an inverted
microscope at a 200× magnification. Each follicle image
was captured by a cooled charge-coupled device camera
system (DP-50; Olympus, Tokyo, Japan), and follicle diam-
eter was measured using Image J imaging system software
version 1.43 (National Institutes of Health, Bethesda, MD).
A total of 500 μL conditioned medium was refreshed with
preincubated medium every 2 days (day 2, 4, 6, 8, 10, and
12). The spent media collected on the indicated days were
pooled per culture plate and frozen at −80°C for a succes-
sive E2 determination. When follicles clearly formed an
antral-like cavity on day 12, ovulation and meiotic resump-
tion were induced by refreshing media with culture media
supplemented with 5 IU/mL human chorionic gonado-
tropin (hCG, Mochida Pharmaceutical Co., Tokyo, Japan).
On day 13, follicles were checked for ovulation 16 h after
hCG administration, and ovulation was considered
when the follicle was visually ruptured and the cumulus
oocyte complex (COC) extruded from the follicles. The
ovulated COCs were evaluated for cumulus expansion
and germinal vesicle breakdown (GVBD), indicating
meiotic resumption of oocytes, after removing the sur-
rounding cumulus cells by repeated pipetting in the
presence of 300 IU/mL hyaluronidase.Assessment of follicle survival
Using the method reported by Adriaenssens et al. [27] and
Lenie et al. [28], we assessed follicle morphology and classi-
fied the follicular development stage as follicular, diffuse, or
antral in the in vitro preantral follicle culture. Briefly, the
follicular stage is characterized by preservation of the fol-
licle basal membrane. Initially, theca cells grow out to the
culture plate and granulosa cell proliferation is limited.
The follicles remain in this stage until day 4 of culture. The
diffuse stage is characterized by marked granulosa cell pro-
liferation and a large preantral follicle. From day 4 to day 6
of culture, granulosa cells overgrow the theca cell mono-
layer through the basement membrane, and the follicles
gradually enlarge. From day 6 or 8 up to day 12 of culture,
granulosa cells differentiate into 2 spatially and functionally
distinct populations, cumulus cells and mural granulosa
cells, and the follicles form an antral-like cavity, which
characterizes the antral stage.
In this culture system, surviving follicles were defined as
those that could retain their oocyte completely embedded
within the granulosa cell mass and that exhibited no signs
of degeneration [28,29]. Follicle degeneration was charac-
terized by failure of the granulosa cells to multiply, release
oocytes, or by collapse [28].17β-estradiol measurement
Media cultured with individual mouse follicles were re-
placed every other day, and the collected media were
pooled and stored at −80°C until the measurement of E2
levels was performed. E2 levels in the collected culture
media were measured using the estradiol enzyme immuno-
assay kit (Estradiol EIA Kit) (catalogue no. 582251; Cayman
Chemical Co., Ann Arbor, MI) according to the manufac-
turer’s protocol. Culture media from non-surviving follicles
were excluded from the experiment.
Experimental conditions and evaluation parameters
In this experiment, the control group consisted of follicles
cultured in media without FSH in the presence of the ve-
hicle. All compounds were added to the culture media dur-
ing the in vitro culture period. TNF-α was dissolved in
distilled water at 10 μg/mL and was stored at −80°C until
use. Pioglitazone was dissolved in dimethyl sulfoxide
(DMSO) at 10 mM and was stocked at −80°C until use.
The final concentration of DMSO in the medium never
exceeded 0.1%. In the preliminary study, we tested the ef-
fects of DMSO as a vehicle on follicle development. There
were no significant differences of follicle development be-
tween the groups treated with and without DMSO (data
not shown).
Effects of various treatments on follicle development and
steroidogenesis were evaluated as follows: follicle diameter,
follicle survival, antral-like cavity formation, and measure-
ment of E2 concentration in culture media. Moreover, we
evaluated the effects of various treatments on ovulation
and GVBD, indicating resumption of meiosis.
We previously demonstrated that TNF-α significantly
inhibited FSH-induced follicular development and ste-
roidogenesis in a dose-dependent manner [23]. In the
present study, we examined the effects of pioglitazone
on the follicle development and steroidogenesis by using
the in vitro follicle culture system. Experimental scheme
shows in Figure 1.
Statistical analysis
All experiments consisted of at least 5 independent experi-
mental runs. Differences between means were calculated
by one-way ANOVA, followed by a post hoc test, and data
expressed as percentages were analyzed by Fisher’s exact
probability test using GraphPad Prism version 5.0 for Win-
dows (GraphPad Software Inc., San Diego, CA). Values are
given as mean ± SEM. Significant differences are defined as
P < 0.05.
Results
Our previous data show that 100 mIU/mL of FSH treat-
ment significantly induced the follicle growth and increase
in E2 concentration in the culture medium compared to
control samples without FSH treatment [23]. While follicles
Figure 1 Study scheme. Scheme used for in vitro culture of mouse follicles for the assessment of follicle diameter, follicle survival, antral-like
cavity formation, 17β-estradiol (E2) concentration in the culture media, ovulation, and germinal vesicle breakdown (GVBD) after human chorionic
gonadotropin (hCG)treatment is shown. Early preantral follicles were mechanically isolated from mice ovaries as described in Methods. Collected
follicles were individually cultured per well in a 24-well plate for 12 days. Follicles were cultured with various treatments. The follicles were
inspected for morphology, follicle survival, and antral-like cavity formation every other day as described in Methods. Media were refreshed every
other day, and E2 concentrations in the collected media were measured. After 12 days of culture, hCG (5 IU/mL) was added to the culture media
to induce ovulation. After 16 h of hCG treatment, ovulation and GVBD were evaluated.
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panel), follicles cultured with FSH grew larger and formed
an antral-like cavity at 10 to 12 days of culture (Figure 2,
lower panel).
TNF-α is a pro-inflammatory cytokine that induces cell
death [30]. TNF-α also influences follicle development and
steroidogenesis [11]. Further, in patients with PCOS, serum
and follicular fluid levels of TNF-α are higher than in pa-
tients without PCOS [31,32]. Therefore, we examined the
effects of TNF-α on follicular development. In the in vitro
culture, TNF-α significantly inhibited FSH-induced follicu-
lar development and steroidogenesis in a dose-dependent
manner with a minimal effective dose of 5 ng/mL. There-
fore, we used the in vitro preantral follicle culture system
with TNF-α as a model to study follicular development
of PCOS.
We examined whether pioglitazone could counteract
the inhibition of FSH-induced follicular development
and steroidogenesis by TNF-α. Pioglitazone signifi-
cantly counteracted the inhibition of FSH-induced fol-
licular development and steroidogenesis by TNF-α in a
dose-dependent manner (Figure 3). TNF-α (5 ng/mL)Figure 2 In vitro mouse preantral follicle culture system and the effec
development treated with or without follicle stimulating hormone (FSH) (1
(control) grew in a multilayered pattern and did not survive. On the other
antral-like cavities at 10 to 12 days of culture. The cumulus oocyte complex
administration of 5 IU/mL of hCG (inset). Bar = 100 μm.inhibited the FSH-induced follicle survival rate. Although
1 μM of pioglitazone failed to show an effect, both 5 and
10 μM of pioglitazone significantly counteracted the
inhibition of FSH-induced follicle survival by TNF-α
(Figure 3A). TNF-α inhibited the FSH-induced antral-like
cavity formation rate. Although 1 μM of pioglitazone
failed to show an effect, both 5 and 10 μM of pioglitazone
significantly counteracted the inhibition of FSH-induced
antral-like cavity formation rates by TNF-α. TNF-α
(5 ng/mL) inhibited the FSH-induced E2 production
(Figure 3C). Although 1 μM of pioglitazone failed to show
an effect, both 5 and 10 μM of pioglitazone counteracted
the inhibition of FSH-induced E2 production by TNF-α
(Figure 3C). While TNF-α significantly decreased FSH-
induced follicle diameter at 12 days of culture, pioglitazone
did not counteract the inhibition by TNF-α in follicle
diameter at 12 days of culture (Figure 3D).
We examined the effects of pioglitazone on the hCG-
induced ovulation and meiotic resumption of oocytes
with or without FSH and TNF-α (Table 1). While TNF-α
(5 ng/mL) inhibited the hCG-induced ovulation rate in
the FSH-treated group, pioglitazone (5 μM) significantlyts of FSH on follicular development. Examples of follicular
00 mIU/mL) are shown. The majority of follicles not treated with FSH
hand, follicles cultured with FSH (100 mIU/mL) grew larger and formed
was visibly extruded from the antral-like cavity after 16 h of the
Figure 3 Pioglitazone counteracts the inhibition of FSH-induced follicular development and steroidogenesis by TNF-α. Effects of
pioglitazone on the inhibition of follicle-stimulating hormone (FSH)-induced follicular development and steroidogenesis by tumor necrosis factor-
α (TNF-α). Follicles were cultured with 1, 5, 10 μM of pioglitazone in the presence or absence of 5 ng/mL of TNF-α or 100 mIU/mL of FSH. A)
Follicle survival rates at 12 days of culture with various treatments are shown. Numbers inside bars indicate the number of surviving follicles/total
tested follicles. B) Antral-like cavity formation rates at 12 days of culture with various treatments are shown. Numbers inside bars indicate the
number of follicles with antral-like cavity/total tested follicles. C) 17β-estradiol (E2)concentrations in the culture media at 12 days of culture with
various treatments are shown. D) Follicle diameters at 12 days of culture with various treatments are shown. Data are shown as the mean ± SEM.
The group treated only with dimethyl sulfoxide (DMSO) was used as a control. Bars with different letters represent a significant difference
(P < 0.05).
Table 1 Effects of pioglitazone on ovulation and meiotic resumption in follicles treated with FSH and TNF-α
Treatment Number of ovulated follicles/
total tested follicles (%)
Number of ovulated follicles/number of follicles
with antral-like cavity formation (%)
Number of GVDB oocytes/
number of ovulated COCs (%)
Control (DMSO) 0/87 (0)a 0/0 (0)a 0/0 (0)a
TNF-α (5 ng/mL) 0/72 (0)a 0/0 (0)a 0/0 (0)a
Pioglitazone (5 μM) 0/80 (0)a 0/0 (0)a 0/0 (0)a
FSH (100 mIU/mL) 60/126 (48)b 60/81 (74)b 60/60 (100)b
FSH + TNF-α (5 ng/mL) 14/150 (99)c 14/44 (32)c 14/14 (100)b
FSH + TNF-α (5 ng/mL) +
pioglitazone (5 μM)
35/125 (28)d 35/60 (58)d 35/35 (100)b
FSH, follicle stimulating hormone; TNF-α, tumor necrosis factor-α; DMSO, dimethyl sulfoxide; GVBD, germinal vesicle breakdown; COCs, cumulus oocyte complexes.
a-d Values with different superscript letters within the same column differ significantly. P < 0.05.
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total tested follicles and follicles with antral-like cavity
formation by TNF-α in the FSH-treated groups. All oo-
cytes underwent GVBD after COC ovulation in the
FSH-treated groups.
Discussion
In the present study, we examined the direct effects of
pioglitazone on the follicular development and steroido-
genesis by using an in vitro mouse preantral follicle culture
system. While TNF-α inhibited the FSH-induced follicle
development, such as follicle survival, antral-like cavity for-
mation, and E2 production, pioglitazone counteracted
these inhibitory effects by TNF-α.
In vitro mouse ovarian culture methods provide a useful
tool for studying follicle development [23,33-35]. We
employed an in vitro mouse ovarian follicle culture system
for up to 12 days to study the effects of various compounds
on FSH-induced follicle development and steroidogenesis.
The mechanism of TNF-α inhibition of FSH-induced
follicle development and steroidogenesis remains un-
known. TNF-α is a well-known cytokine that is capable of
inducing apoptosis in cells [30]. TNF-α is also known as
adipocytokine that can induce insulin resistance [36]. In
the ovary, TNF-α is critically involved in the follicles apop-
tosis [9,10]. Moreover, TNF-α has direct effects on ovarian
steroidogenesis [11,37]. Several studies have reported that
TNF-α decreased steroidogenic acute regulatory protein
(StAR) mRNA and protein levels [38,39].
In the present study, we showed that pioglitazone
counteracted the TNF-α inhibition in FSH-induced follicle
development and steroidogenesis in an in vitro culture
system. The precise mechanisms of restoration of TNF-α
inhibition of FSH-induced follicle development and ste-
roidogenesis by pioglitazone were unknown. Recently, we
examined whether bezafibrate, a ligand for PPARs (α, δ, γ)
rescued the TNF-α inhibition of follicular development
and steroidogenesis [23]. Our previous data showed that
PPAR-γ was expressed in mouse preantral follicles and
that GW1929, a selective PPAR-γ agonist, counteracted
the inhibition of FSH-induced follicular development by
TNF-α. Furthermore, GW9662, a selective PPAR-γ antag-
onist, canceled the restorative effects of bezafibrate on the
inhibition of FSH-induced follicular development and
steroidogenesis by TNF-α. Therefore, we suggested that,
among the three PPARs, PPAR-γ is important for follicu-
lar development. In fact, it is reported that deletion of
PPAR-γ results in impaired fertility in genetically targeted
mice [40].
It is well known that thiazolidinediones, such as
pioglitazone and rosiglitazone, specifically bind to PPAR-γ,
which is located on macrophages, adipose tissue or hu-
man granulosa lutein cells [18,41]. Pioglitazone is a
thiazolidinedione derivative that acts by improvinginsulin resistance via the PPAR-γ pathway. Pioglitazone
improves peripheral insulin resistance, ovulation, and
hyperandrogenism in women with PCOS [42-44]. Seto-
Young et al. reported that pioglitazone has a direct action
on the human ovary [22]. Kim et al. showed that pio-
glitazone decreased the follicular fluid levels of TNF-α in
patients with PCOS [45]. Moreover, several reports have
demonstrated that PPAR-γ activation reduced the expres-
sion of TNF-α and other inflammatory cytokines in vivo
[46,47]. Pioglitazone may act on PPAR-γ and reduce
TNF-α. However, the detailed pathway through which
pioglitazone suppresses TNF-α is unclear. Further exami-
nations are needed to determine the detailed mechanism
by which pioglitazone affects follicular development.
Conclusions
Pioglitazone counteracted the inhibition of FSH-induced
follicular development and steroidogenesis by TNF-α.
These results suggest that pioglitazone may directly act on
ovarian functions through PPAR-γ activation in patients
with PCOS.
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